Access to Monoclonal Antibodies
Recent News
- Country level factsheets
- Regional factsheets
- Social media toolkit
- Issue brief
Resources
- Peer reviewed paper
- Grey literature
- Other peer reviewed paper
- Important website
mAbs Watch
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Global mAbs Access
| Access Metric | Goal | Current |
|---|---|---|
| Example | 1 | 1 |
| Example | 2 | 2 |
| Example | 3 | 3 |
| Example | 4 | 4 |
| Example | 5 | 5 |
| Example | 6 | 6 |
| Example | 7 | 7 |
| Example | 8 | 8 |
| Example | 9 | 9 |
Target Access Profiles
mAbs Access Coalition
mAbs Access Coalition (MAC) is …. Monoclonal antibodies (mAbs) are a growing class of biological medicine that have been approved for several noncommunicable diseases and demonstrate great potential to effectively prevent and treat a range of infectious diseases. Yet, significant barriers to access persist — including intellectual property, regulatory barriers, and high prices.